Skip to main content

Table 3 Time trends in prevalence of medical comorbidity (in %) from 1993 to 2005 in patients undergoing primary THA

From: Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: A 13-year study of time trends

 

1993-1995

1996-1998

1999-2001

2002-2005

P-value

Deyo-Charlson comorbidities

 Myocardial Infarction

4.0

4.2

4.1

4.7

0.76

 Congestive Heart Failure

2.5

2.8

3.5

4.1

0.05

 Peripheral Vascular Disease

4.7

3.8

4.2

5.6

0.07

 Cerebrovascular disease

5.5

5.2

6.3

7.9

0.006

 Dementia

0

0

0.3

0.4

0.02

 COPD

9.7

8.8

10.2

9.7

0.66

 Peptic ulcer disease

5.5

6.3

6.2

6.3

0.81

 Mild liver disease

1.4

0.6

1.1

1.2

0.20

 Diabetes

4.8

5.0

5.9

8.0

<0.001

 Diabetes with end organ damage

0.9

0.7

1.8

2.0

0.005

 Hemiplegia

0.3

0.2

0.2

0.5

0.48

 Moderate/severe renal disease

2.6

3.2

5.4

5.9

<0.001

 Moderate/severe liver disease

0.5

0.3

0.2

0.3

0.58

 Metastatic solid tumor

3.3

2.3

3.6

2.7

0.12

 AIDS

0

0.1

0

0

0.32

 Rheumatologic disease

6.1

5.2

5.4

5.2

0.67

 Other cancer

11.2

10.9

13.5

13.9

0.02

Mean Deyo-Charlson score (SD)

0.9 (1.8)

0.9 (1.7)

1.1 (2.0)

1.1 (2.0)

<0.001

  1. COPD, Chronic Obstructive Pulmonary Disease; AIDS, Acquired Immune Deficiency Disease; SD, standard deviation.
  2. Significant p-values are in bold, calculated with chi-squared test.